INTRODUCTION
As the most common medical complaint in the United States, pain represents a significant public health burden, with estimated annual direct and indirect costs exceeding $600 billion [1] . Opioids are the most widely used analgesic and part of a multimodal pain management approach [2] [3] [4] [5] . In 2012, health care professionals wrote more than 259 million prescriptions for opioid analgesics [6] . Careful monitoring and judicious use are warranted, as opioids are associated with life-threatening adverse events, such as respiratory depression, and there is also potential for diversion and misuse [7] [8] [9] [10] [11] [12] . Opioid-induced nausea and vomiting (OINV), a common adverse event in patients using opioid therapy for acute pain, can be a significant barrier to effective pain management [13] [14] [15] [16] [17] . Published reports of OINV suggest that nausea develops in approximately 40% of patients and vomiting develops in approximately 20% of patients, both of which may have a higher incidence in clinical practice [18] [19] [20] [21] [22] [23] . In a systematic review of opioid-related adverse events in postoperative patients, 31% reported gastrointestinal adverse events, such as nausea, vomiting, and constipation [24] .
Gastrointestinal adverse events may be a contributing factor to treatment discontinuation [10] . Survey data have shown that, to reduce gastrointestinal-related adverse events, including nausea, vomiting, or constipation, 13% of patients with acute pain discontinued their opioid treatment, and 16%
of patients with acute pain reduced their dose of opioids [25] . Inadequately treated acute pain has been associated with an increased risk of progression to chronic pain [10, [26] [27] [28] . In addition, studies have shown that inadequately treated acute pain may also result in problems ranging from sleep impairment to the development of depression or post-traumatic stress disorder [29, 30] . Thus, OINV may significantly compromise effective pain management increasing overall health care utilization and associated costs [10, 25, 31] .
While there are ample data regarding the economic consequences of nausea and vomiting (NV) in the hospital setting [23, [32] [33] [34] [35] , corresponding data in the outpatient setting are limited. A previous study that examined the costs of gastrointestinal events in outpatients treated with immediate-release (IR) opioids for noncancer pain found that NV was associated with increased all-cause health care utilization and costs over a 3-month follow-up period [31] . However, as OINV typically occurs early in treatment and resolves as tolerance develops [36, 37] , economic outcomes collected over this timeframe may not be applicable for shorter-term treatment. Although antiemetics are effective in preventing and alleviating OINV, data pertaining to the rate of antiemetic co-prescribing are scarce.
The objectives of this real-world study were to describe antiemetic usage and to estimate the economic burden associated with NV over a 30-day follow-up period among a large cohort of outpatients receiving IR opioids for the management of acute pain from the perspective of a US commercial health plan.
METHODS

Patient Eligibility and Study Design
A retrospective analysis was conducted using 
IMS
Study Outcomes
Measures of all-cause health care resource utilization were hospitalizations (including 30-day readmission rates among a subgroup of patients), emergency department (ED) visits, and physician office visits. The prescribing rate of antiemetics was examined. All-cause health care costs (2013-2014 USD) were calculated for inpatient, outpatient, and pharmacy services using the allowed reimbursement payment amount (inclusive of patient copay).
Statistical Analysis
Patients with a medical claim for NV with or without a pharmacy claim for an antiemetic agent (NV group) were compared with patients having no medical claim for NV and no pharmacy claim for an antiemetic agent (no NV group). The incremental impact of NV on health care resource utilization and costs over the 30-day follow-up period was examined. The rate of antiemetic use in the overall study population was examined. In addition, rates of 30-day rehospitalization among the subgroup of patients who were hospitalized within 2 days of filling the index opioid prescription were compared between patients with and without a medical claim for NV during study follow-up. Antiemetics can be used for reasons other than NV, and therefore, patients with a pharmacy claim for an antiemetic agent, but no medical claim for NV were excluded from health care resource use and cost comparisons. Descriptive data were compared using t-tests and Chi-squared tests for continuous and categorical variables, respectively. Propensity score matching (PSM) [38] , using the Greedy method with a caliper of 0.01, was used to adjust for known differences in baseline patient characteristics. Patients were matched on age, gender, type of index opioid, health plan characteristics and baseline antiemetic claims, NV claims, total health care costs, and severity of comorbid conditions using the Charlson Comorbidity Index [39] . Health care resource utilization and costs were assessed using the propensity-matched cohorts.
Due to a residual imbalance between propensity-matched groups, regression analyses were conducted to generate adjusted cost ratios and their 95% confidence intervals (CI), accounting for differences in baseline antiemetic use. Generalized linear models (GLM) with log-link and gamma distribution were used to adjust pharmacy and total costs.
Adjustment of inpatient and outpatient costs required the use of a two-part model, due to the large numbers of patients with zero costs; logistic regression was used to estimate the probability of having a positive cost, and GLM with log-link and gamma distribution was used to estimate the cost conditional on it being positive.
For the subgroup analysis of patients hospitalized within 2 days of filling index opioid prescription, Kaplan-Meier curves were generated to estimate 30-day rehospitalization rates. All P values were considered to be significant at P\0.05. Analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC, USA).
RESULTS
Study eligibility was met by 2,120,806 patients (Table S1 ). Of the total cohort of eligible patients receiving an IR opioid prescription, 2.3% (n = 47,935) had a medical claim for NV within 30 days of index opioid prescription, with the majority of these patients (57.1%, n = 27,375) having an NV claim occurring on the index date (Fig. 2) . Of patients with an NV claim on the same day as the index opioid prescription, 52.0% (n = 14,242) were also co-prescribed an antiemetic.
Among all eligible patients receiving an IR opioid prescription, 10.2% (n = 215,366) filled an antiemetic prescription within 30 days after the index opioid prescription, and most of these patients (73.7%, n = 158,859) received the antiemetic on the same day as the index opioid prescription. Among patients who filled an antiemetic prescription on the same date as the index opioid prescription, 9.0%
(n = 14,242) also had an NV claim on the index date (Fig. 2 2-1.3) , and 2.7 (2.7-2.8) for inpatient, outpatient, pharmacy, and total costs, respectively. In both groups, the majority of the expenditures were for outpatient visits (68.0% in patients with a NV claim and 80.4% in patients with no NV claim); however, the greatest cost differential was for inpatient services.
DISCUSSION
In this study of patients newly treated with an IR opioid prescribed for acute pain, NV coincident with opioid use was associated with a significant economic burden. Total adjusted health care costs were more than 1.5 times higher for patients with a NV claim compared with those with no NV claim, and for inpatient services, the adjusted costs were more than five times higher over the 30-day follow-up period.
Furthermore, in the subgroup of patients with a recent hospitalization, 30-day hospital readmission rates were more than seven times [40] .
The direction of our results is consistent with an earlier study that examined the costs of gastrointestinal events in outpatients treated with IR opioids for noncancer pain [31] . In that study, total health care costs over a three-month follow-up period were more than 200% higher in patients with a medical claim for NV ($12,576) compared with patients with no medical claim for a gastrointestinal event ($3981), primarily driven by hospital costs ($7025 vs $1356, respectively). It is possible that differences in the total cost ratios may be due to differences in timing of data collection relative to the index date (1 vs 3 months) or cohort selection definitions (e.g., patients with no medical claims for NV vs patients with no medical claims for an opioid-related gastrointestinal event).
Other studies that have evaluated the economic impact of NV associated with opioid use have largely been conducted in the inpatient setting. In a retrospective study of adult surgical patients, median total health care costs were increased by 7.6% and median length of hospital stay was increased by 10.3% in patients who experienced opioid-related adverse drug events (ADEs) versus matched controls who did not experience such events [35] . Of note, NV accounted for approximately ED emergency department, NV nausea and vomiting, PPPM per-patient-per-month, PTPPM per-treated-patient-per month, SD standard deviation * P\0.0001
50% of all opioid-related ADEs in this study. In another study among hospitalized patients who received oral opioids, those who received medication for nausea, vomiting, or constipation were hospitalized 1.36 days longer than those who did not receive any such medication, at an additional cost of $2223 per patient (both P\0.0001) [41] . Medication for nausea, vomiting, or constipation was also associated with a longer hospital length of stay and greater costs per patient among patients who received injectable (including epidural) opioids in that study [41] .
The prevalence of NV claims coincident with short-term opioid use in this study was much lower (2.3%) than rates of OINV reported spontaneously in the previous clinical trials [18] [19] [20] [21] [22] , suggesting the underreporting of these side effects to treating providers. In a retrospective survey of oral opioid users with acute pain, 77% of patients with nausea and 65% with vomiting did not inform their physician of these side effects [13] . 
